Compare MKTX & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MKTX | GKOS |
|---|---|---|
| Founded | 2000 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.0B |
| IPO Year | 2004 | 2015 |
| Metric | MKTX | GKOS |
|---|---|---|
| Price | $176.86 | $120.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $206.29 | $133.07 |
| AVG Volume (30 Days) | 366.2K | ★ 653.9K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.64 | N/A |
| Revenue | $397,471,000.00 | ★ $507,442,000.00 |
| Revenue This Year | $9.91 | $23.30 |
| Revenue Next Year | $7.38 | $27.43 |
| P/E Ratio | $26.48 | ★ N/A |
| Revenue Growth | 7.45 | ★ 32.33 |
| 52 Week Low | $156.17 | $73.16 |
| 52 Week High | $232.84 | $130.23 |
| Indicator | MKTX | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 64.03 |
| Support Level | $159.39 | $81.54 |
| Resistance Level | $183.23 | $123.16 |
| Average True Range (ATR) | 4.76 | 4.63 |
| MACD | 0.90 | 2.02 |
| Stochastic Oscillator | 79.15 | 88.93 |
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.